Synapse - Anas Younes

Results (320)

Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): Updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin's lymphoma (NHL)

Meeting Abstract

Younes, A.; Flinn, I.; Berdeja, J.; Friedberg, J. W.; Casulo, C.; Thieblemont, C.; Morschhauser, F.; Westin, J. R.; Seetharam, S.; Hellemans, P.; more...
Blood (2013)

Fulltext@MSK | Save

A phase I study of an anti-CD30 x anti-CD16A bispecific tandab antibody, AFM13, in patients with relapsed or refractory Hodgkin lymphoma

Meeting Abstract

Zhukovsky, E.; Rothe, A.; von Tresckow, B.; Topp, M.; Younes, A.; Eichenauer, D. A.; Hummel, H.; Reiners, K. S.; Dietlein, M.; Kessler, J.; more...
Blood (2013)

Fulltext@MSK | Save

Phase II trial of bortezomib in combination with fractionated cyclophosphamide and rituximab (BCR) for relapsed/refractory mantle cell lymphoma (MCL)

Meeting Abstract

Romaguera, J. E.; Fanale, M. A.; Samaniego, F.; Fayad, L. E.; Hagemeister, F. B.; McLaughlin, P.; Rodriguez, M. A.; Weaver, P.; Hartig, K.; Badillo, M.; more...
Blood (2013)

Fulltext@MSK | Save

FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma

Meeting Abstract

Moskowitz, A.; Schoder, H.; Gerecitano, J. F.; Hamlin, P.; Horwitz, S. M.; Matasar, M. J.; Keskinyan, V. S.; McCall, S.; Noy, A.; Palomba, M. L.; more...
Blood (2013)

Fulltext@MSK | Save

Profiling genomic alterations of diffuse large B-cell lymphoma (DLBCL) at diagnosis, relapse, and transformation, using a novel clinical diagnostic targeted sequencing platform

Meeting Abstract

Intlekofer, A. M.; Sheshan, V. E.; Levine, R. L.; Zelenetz, A. D.; Teruya-Feldstein, J.; Dogan, A.; Palomba, M. L.; Moskowitz, C. H.; van den Brink, M. R. M.; Knapp, K. M.; more...
Blood (2013)

Fulltext@MSK | Save

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo) substituted for non-liposomal vincristine in CHOP with or without rituximab for patients with untreated aggressive non-Hodgkin's lymphomas